EUCTR2009-014493-18-PLActive, not recruitingNot Applicable
A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of rLP2086 Vaccine When Administered inEither 2- or 3-Dose Regimens in Healthy Subjects Aged =11 to <19 Years
Pfizer Inc 235 East 42nd Street, New York, NY100170 sites1,714 target enrollmentStarted: July 1, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 1,714
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator’s study team before subjects are included in the study.
- •1.Evidence of a personally signed and dated informed consent document indicating that the parent/legally acceptable representative and/or subject has been informed of all pertinent aspects of the study.
- •2.Parent/legally acceptable representative and/or subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •3.Male or female subject aged =11 and <19 years at the time of enrollment.
- •4.Available for the entire study period and can be reached by telephone.
- •5.Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
- •6.All male and female subjects must agree to practice a form of effective contraception, such as barrier contraception (ie, condom plus spermicide, a female condom, diaphragm, cervical cap or intrauterine device), implants, injectables, combined oral contraceptives or sexual abstinence prior to entering into the study, for the duration of the vaccination period and for 28 days after the last study vaccination. For Germany: The phrase sexual abstinence is not applicable, with the understanding that all male and all female subjects of childbearing potential must practice an effective form of contraception during the study.
- •7.Negative urine pregnancy test for female subjects.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1524
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 190
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Subjects presenting with any of the following will not be included in the study:
- •1.Previous vaccination with any meningococcal serogroup B vaccine.
- •2.A previous anaphylactic reaction to any vaccine or vaccine-related component.
- •3.Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
- •4.A known or suspected disease of the immune system or those receiving immunosuppressive therapy.
- •5.History of culture-proven disease caused by Neisseria meningitidis or Neisseria gonorrhoeae.
- •6.Significant neurological disorder or history of seizure (excluding simple febrile seizure).
- •7.Receipt of any blood products, including immunoglobulin within 6 months before the first study vaccination.
- •8.Current chronic use of systemic antibiotics.
- •9.Participation in other studies during study participation. Participation in purely observational studies is acceptable.
- •10.Received any investigational drugs, vaccines or devices within 28 days before administration of the first study vaccination.
- •11.Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
- •12.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •13.Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
- •14.Subject is a direct descendant (e.g., child, grandchild or other family member) of study site or Pfizer personnel.
- •15.Subject is pregnant or breastfeeding.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A clinical trial to determine if the investigational MnB vaccine works when 2 or 3 doses of the vaccine is given to adolescents.Healthy volunteers (prevention of bacterial meningitis).MedDRA version: 14.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-014493-18-SEPfizer Inc 235 East 42nd Street, New York, NY100171,714
Active, not recruiting
Phase 1
A clinical trial to determine if the investigational MnB vaccine works when 2 or 3 doses of the vaccine is given to adolescents.Healthy volunteers (prevention of bacterial meningitis).MedDRA version: 14.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-014493-18-ESPFIZER S.L.U.1,712
Active, not recruiting
Not Applicable
A clinical trial to determine if the investigational MnB vaccine works when 2 or 3 doses of the vaccine is given to adolescents.Healthy volunteers (prevention of bacterial meningitis).MedDRA version: 14.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-014493-18-DEPfizer Inc 235 East 42nd Street, New York, NY10017 US1,714
Active, not recruiting
Not Applicable
A clinical trial to determine if the investigational MnB vaccine works when 2 or 3 doses of the vaccine is given to adolescents.Healthy volunteers (prevention of bacterial meningitis).MedDRA version: 14.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-014493-18-FIPfizer Inc 235 East 42nd Street, New York, NY100171,714
Active, not recruiting
Not Applicable
A clinical trial to determine if the investigational MnB vaccine works when 2 or 3 doses of the vaccine is given to adolescents.EUCTR2009-014493-18-CZPfizer Inc.1,714